Are you Dr. Crombez?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
10833 Le Conte Ave
12-441 Mdcc
Los Angeles, CA 90095Phone+1 310-206-3952Fax+1 310-206-0209
Summary
- Dr. Eric Crombez, MD is a medical geneticist in Los Angeles, California.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 2000 - 2005
Wayne State University School of MedicineClass of 2000
Clinical Trials
- Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase Start of enrollment: 2007 Jul 25
- Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) Start of enrollment: 2012 Feb 02
Publications & Presentations
PubMed
- 71 citationsSafety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuriaPhillip Lee, Eileen P. Treacy, Eric Crombez, Melissa P. Wasserstein, Lewis Waber
American Journal of Medical Genetics. Part A. 2008-11-15 - 141 citationsEfficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controll...Friedrich K. Trefz, Barbara K. Burton, Nicola Longo, Mercedes Martinez Pardo Casanova, Daniel Gruskin
The Journal of Pediatrics. 2009-05-01 - 92 citationsHyperargininemia due to liver arginase deficiency.Eric Crombez, Stephen D. Cederbaum
Molecular Genetics and Metabolism. 2005-03-01
Press Mentions
Gene Therapy Redosing Gains Traction as Need Grows and Novel Strategies EmergeOctober 20th, 2021- Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy ProgramApril 22nd, 2021
- Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson DiseaseDecember 9th, 2020
- Join now to see all
